Robyn J. Puro

605 total citations
16 papers, 475 citations indexed

About

Robyn J. Puro is a scholar working on Immunology, Epidemiology and Oncology. According to data from OpenAlex, Robyn J. Puro has authored 16 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 3 papers in Epidemiology and 2 papers in Oncology. Recurrent topics in Robyn J. Puro's work include Phagocytosis and Immune Regulation (11 papers), Immunotherapy and Immune Responses (8 papers) and Immune cells in cancer (3 papers). Robyn J. Puro is often cited by papers focused on Phagocytosis and Immune Regulation (11 papers), Immunotherapy and Immune Responses (8 papers) and Immune cells in cancer (3 papers). Robyn J. Puro collaborates with scholars based in United States and Canada. Robyn J. Puro's co-authors include Robert J. Schneider, Michael Biermer, Lihua Wang, Michael J. Bouchard, Ronald R. Hiebsch, Benjamin J. Capoccia, Hubert Hilbi, Arturo Zychlinsky, Gabriela Andrejeva and Myriam N. Bouchlaka and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Robyn J. Puro

16 papers receiving 468 citations

Peers

Countries citing papers authored by Robyn J. Puro

Since Specialization

Citations

This map shows the geographic impact of Robyn J. Puro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robyn J. Puro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robyn J. Puro more than expected).

Fields of papers citing papers by Robyn J. Puro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robyn J. Puro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robyn J. Puro. The network helps show where Robyn J. Puro may publish in the future.

Co-authorship network of co-authors of Robyn J. Puro

This figure shows the co-authorship network connecting the top 25 collaborators of Robyn J. Puro. A scholar is included among the top collaborators of Robyn J. Puro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robyn J. Puro. Robyn J. Puro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells 2021 ·The Journal of Immunology ·Gabriela Andrejeva, Benjamin J. Capoccia, Ronald R. Hiebsch, (unknown), Isra Darwech, Robyn J. Puro, (unknown)	48
2	AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms 2021 ·Blood ·(unknown), John O. Richards, Gabriela Andrejeva, Benjamin J. Capoccia, Robyn J. Puro, (unknown), Ronald R. Hiebsch, A.K. Kashyap, (unknown)	2
3	AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics 2020 ·Blood ·(unknown), John O. Richards, Robyn J. Puro, Gabriela Andrejeva, Ben Capoccia, (unknown), Ronald R. Hiebsch, (unknown), Victoria Sung, (unknown)	12
4	Pre-Clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia 2020 ·Blood ·(unknown), Willie Wilson, Isra Darwech, Gabriela Andrejeva, Benjamin J. Capoccia, Robyn J. Puro, A.K. Kashyap, (unknown)	2
5	Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding 2019 ·Molecular Cancer Therapeutics ·Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, (unknown), Pamela T. Manning, William A. Frazier, Robert W. Karr, (unknown)	67
6	Abstract 540: AO-176, a normal cell sparing humanized anti-CD47 antibody 2019 ·Cancer Research ·Prabir K. Chakraborty, Myriam N. Bouchlaka, Benjamin J. Capoccia, Ronald R. Hiebsch, (unknown), Robyn J. Puro, (unknown), (unknown)	1
7	Abstract B100: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination antitumor efficacy with chemotherapy and targeted antibodies 2019 ·Molecular Cancer Therapeutics ·(unknown), Myriam N. Bouchlaka, Robyn J. Puro, Ben Capoccia, Ronald R. Hiebsch, (unknown), (unknown), (unknown), (unknown)	2
8	Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination 2019 ·Blood ·John O. Richards, Myriam N. Bouchlaka, Robyn J. Puro, Ben Capoccia, Ronald R. Hiebsch, (unknown), Willie Wilson, (unknown), Victoria Sung, (unknown)	5
9	Abstract A147: AO-176, a next-generation anti-CD47 antibody, induces immunogenic cell death 2019 ·Cancer Immunology Research ·(unknown), Benjamin J. Capoccia, Ronald R. Hiebsch, (unknown), (unknown), Robyn J. Puro, Willie Wilson, Pamela T. Manning, Robert W. Carr	1
10	Abstract 1765: A humanized anti-CD47 monoclonal antibody that directly kills human tumor cells and has additional unique functional characteristics 2018 ·Cancer Research ·Robyn J. Puro, Katherine Liu, Benjamin J. Capoccia, (unknown), Ronald R. Hiebsch, Myriam N. Bouchlaka, (unknown), Pamela T. Manning, (unknown), Robert W. Karr	2
11	Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies 2018 ·Blood ·Willie Wilson, Myriam N. Bouchlaka, Ben Capoccia, Ronald R. Hiebsch, (unknown), Robyn J. Puro, (unknown), (unknown), Pamela T. Manning, Robert W. Karr, (unknown), (unknown)	4
12	Natural IgM Blockade Limits Infarct Expansion and Left Ventricular Dysfunction in a Swine Myocardial Infarct Model 2015 ·Circulation Cardiovascular Interventions ·Smita Sihag, Michael Haas, Karen M. Kim, J. Luis Guerrero, Jonathan Beaudoin, Elisabeth M. Alicot, (unknown), (unknown), Robyn J. Puro, Joren C. Madsen, David H. Sachs, (unknown), Michael C. Carroll, James S. Allan	3
13	Tumor Necrosis Factor Activates a Conserved Innate Antiviral Response to Hepatitis B Virus That Destabilizes Nucleocapsids and Reduces Nuclear Viral DNA 2007 ·Journal of Virology ·Robyn J. Puro, Robert J. Schneider	62
14	Activation and Inhibition of Cellular Calcium and Tyrosine Kinase Signaling Pathways Identify Targets of the HBx Protein Involved in Hepatitis B Virus Replication 2003 ·Journal of Virology ·Michael J. Bouchard, Robyn J. Puro, Lihua Wang, Robert J. Schneider	99
15	Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κB 2003 ·Journal of Virology ·Michael Biermer, Robyn J. Puro, Robert J. Schneider	132
16	Tripeptidyl Peptidase II Promotes Maturation of Caspase-1 inShigella flexneri-Induced Macrophage Apoptosis 2000 ·Infection and Immunity ·Hubert Hilbi, Robyn J. Puro, Arturo Zychlinsky	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact